The procedure was performed in Canada through an international collaboration between partners from Germany, Canada and the UK, who say that this was a case where the placement of the tumour made it impossible to operate without severely impacting the dog’s quality of life. The most suitable treatment was a total excision of the growth and reconstruction with an implant.
The implant was designed with medical CAD tools by German company, Voxelmed, using 3D imaging from the affected area. The dog's veterinary surgeon, Julius Liptak, contributed to the design to ensure it met specifications and allowing him to plan the procedure in advance.
UK company Renishaw then additively manufactured the patient specific implant (PSI) at the Additive Design In Surgical Solutions (ADEISS) Centre in London, Ontario, Canada.
Ed Littlewood, Marketing Manager at Renishaw’s Medical and Dental Products Division said: "Without the advancements in additive manufacturing technology, this dog would not have had such a long and happy future ahead of him.
"Prior to this case, many veterinary surgeons were unaware that the technology was available. Similar procedures are now being planned in Germany and further research is underway to see how animals can benefit from additively manufactured PSIs.
Jan Klasen, veterinary surgeon, 3D designer and CEO of Voxelmed said: "Without AM technology, it would have been almost impossible to reconstruct the dog’s maxilla after tumour removal, because the area was extremely complex in geometry. The implant had to have a similar shape and functionality as the dog’s existing bone structure.
"Using additive manufacturing to maintain the original shape and function of the oral and nasal cavity ensures a high quality of life for the dog, just as a naturally shaped skull and maxilla helps the dog to breathe and eat easily."
To read the full case study, visit http://www.renishaw.com/en/additive-manufacturing-in-veterinary-surgery-saving-a-well-loved-member-of-the-family--42950.
The authors say that whilst it has long been suspected that adverse drug reactions are under-reported, this study is the first to show the scale of the problem, using real data from veterinary clinical records.
For the study, researchers looked for electronic heath records within the Small Animal Veterinary Surveillance Network (SAVSNET) which contained “adverse drug reactions” and “side effects” in the free-text clinical narratives.
The results were then analysed to determine the suspected product, the seriousness and expectedness of the event, and whether the event had been reported to the Veterinary Medicines Directorate or Marketing Authorisation Holders.
Of the 827 cases of suspected adverse drug reactions identified out of a total of 10,565 records reviewed, approximately 90% were not reported.
74% were related to dogs and 70% were listed as “expected” (i.e. already listed in the product information).
The clinical severity of the reaction didn’t appear to impact whether it was reported.
Dr Heather Davies, lead author of the study, said: “As adverse drug reaction reporting rate is directly linked to the regulators ability to mitigate safety issues, this paper is a call to arms encouraging all veterinary professionals to report suspected adverse drug reactions and regulators to make reporting quicker and easier.
"It also the highlights the promise that big real-world data sets hold in enhancing drug safety monitoring processes.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13721
Running throughout October, the campaign is designed to raise awareness among dog owners of how Adaptil Calm can help dogs cope during the fireworks and Christmas party season.
The advertising campaign will target 3.3 million pet owners and it will air on over 60 channels including C4 channels (Channel 4, E4, More4, Film4, Drama, Good Food, Really, W and Home), Sky channels, ITV2 and ITVBe.
Abigail King, behaviour product manager at Ceva Animal Health, said: "The fireworks and party season can be an extremely upsetting time of the year for the nation’s pets.
"By highlighting the benefits of Adaptil at this key time of the year we hope to ensure that dogs are better prepared for the challenges of fireworks and loud noises."
Ceva says the TV advertising campaign will be supported by a digital campaign for both Adaptil and Feliway.
To watch the Adaptil TV advertisement visit https://www.adaptil.com/uk/Success-Stories/Finley.
RCVS Council agreed, in principle, to the sale of Belgravia House and for the College and its London-based staff to move to different premises at its November meeting.
The sale of the building and the move will be overseen by the College’s Estate Strategy Project Board headed by former RCVS President Barry Johnson and including current and former RCVS Council members and RCVS staff.
The RCVS has been based at its current premises in 62-64 Horseferry Road for 25 years, but says it now needs more up-to-date and modern facilities to accommodate a projected increase in the number of staff.
The College says it has considered a number of alternatives, including expanding the current premises by adding or expanding floors. However, due to the fact that the building is in a conservation area, it has become clear that any such expansions would be unlikely to get planning permission from Westminster Council.
Lizzie Lockett, RCVS Chief Executive, said: "For a number of years it has become apparent that it is fast approaching the time at which our current premises will no longer be fit for purpose due to an increase in the number of RCVS staff – something that is projected to continue in the future – the ongoing need to use the building for Disciplinary Hearings, which take over the lion’s share of available meeting space, and the need for better and more modern facilities.
"Even putting our need for increased space on one side, Belgravia House requires major refurbishment in key areas such as air-conditioning and lifts, which would require staff to vacate the premises for up to 18 months, which would be costly and disruptive.
"We are therefore pleased that Council has recognised the need for the College to move somewhere that better reflects our needs and, over the coming months, we will be exploring a number of different options for new premises.
"In parallel to this we have put out an invitation to tender for agents to manage the sale of the building. The plan is for the arrangement to include lease-back so that we have time to find a suitable premises and enabling us to act quickly when we do."
Any organisations that are interested in putting forward a tender to manage the sale of the building should contact Corrie McCann, RCVS Director of Operations, on 020 7202 0724. Responses to tender are required by 30 November 2018.
Photo: Copyright Google 2018
The survey, which received 2445 responses from BVA members, found that 16% of vets and vet students have personally experienced discrimination within a veterinary workplace or learning environment in the past twelve months, while 20% had witnessed discrimination.
Senior colleagues were most commonly responsible for the discrimination (47% of incidents), with discrimination from clients accounting for 35% of incidents.
Sex discrimination was the most common type reported (44% of incidents) and was particularly prevalent in academic settings and in production animal, equine, and mixed practices.
Race discrimination was the next most commonly reported (27% of incidents).
Respondents also gave details of discrimination in relation to other protected characteristics, including age, sexuality, disability and gender reassignment.
Younger vets were more likely than older vets to have personally experienced discrimination in the past year (27% of those under 35 had experienced discrimination).
Female vets were more than twice as likely to have experienced discrimination than their male colleagues (19% and 8% respectively).
The incidence of discrimination was higher amongst vets from a range of minority ethnic backgrounds. Those who described their sexual orientation as bi, gay or lesbian were twice as likely to have personally experienced discrimination in the past year.
Despite the high incidence of discrimination reported, responses to the same survey showed that only 56% of the profession feel concerned about discrimination.
British Veterinary Association Junior Vice President Daniella Dos Santos (pictured right) said: "This is the first time anyone has collected such a significant body of evidence on this issue and the results are truly shocking. It is completely unacceptable that so many members of the veterinary team are subject to discrimination not just from clients but from members of our own profession.
"Worryingly, it seems that the scale of the issue will come as a surprise to many members of our profession and so it is vital that we all join the conversation and reflect on what role we can play to improve equality and inclusion. The veterinary team must become a safe and supportive environment for everyone. We cannot accept anything less for ourselves, for our colleagues and for our profession."
Only 12% of respondents were satisfied with how their incident had been dealt, rising to 23% among those who felt able to report. Daniella said: "Many of the experiences documented in our report are shocking and distressing and this distress is often compounded by what comes next. It was very saddening to hear that so many people have felt unable to report their experiences or that their reports were handled badly by those who received them.
"Experiencing discrimination can be very traumatic, without the ‘double-whammy’ of having your complaint dismissed or mishandled by managers or senior staff. We need to make sure everyone who experiences discrimination is able to get the outcome they deserve.
"Through the discrimination questionnaire we heard many distressing stories from vets, students, vet nurses and other colleagues. We are incredibly grateful to them for sharing these with us so that we can raise awareness of what’s happening in our veterinary workplaces."
To raise awareness of the scale of the issue, the BVA is inviting all members of the veterinary team to join a "Big Conversation on equality and inclusion in the veterinary professions", starting with the release of its report on the current situation on discrimination, which can be downloaded here, then inviting everyone to join online engagement sessions through social media and BVA members to feed in views via their regional representatives ahead of Council on 24 July.
The study, titled “Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010 – 2019)”, also suggests that a urine protein: creatinine greater than 0.5 should prompt reassessment within one week.
For the study, the clinical records of 38 dogs referred to a single university teaching hospital between 2010 and 2019 for treatment of neoplasia with masitinib were retrospectively evaluated.
Data was collected at masitinib initiation and at various timepoints following the start of treatment.
Data gathered included the masitinib dose given and any changes to medication administration or dosing since the previous visit, presence of gross disease and the results of haematology and biochemistry profiles, urinalysis and urine cultures.
Urinalysis results were only included if they were performed at a reference laboratory.
At each timepoint, the urine was classified as non-proteinuric (UP:C ≤0.5) or proteinurinc (UP:C >0.5). Proteinuria was then categorised as likely pre-renal, post-renal, physiological renal or pathological renal.
Dogs were grouped based on the presence or absence of proteinuria at baseline. Non-proteinuric dogs were further divided, based on whether proteinuria developed following treatment during the study.
Of the 28 dogs in the study, five were being treated for epitheliotropic lymphoma, one for vulval lymphoma, one for malignant melanoma and 21 for mast cell tumours.
Twenty-two (79%) dogs were non-proteinuric and six were proteinuric at baseline.
Of the dogs that were non-proteinuric at baseline, four (18.2%) developed proteinuria within one month of treatment initiation. Median time to first detection of proteinuria was 14.5 days (range: 13 to 31).
Of the dogs with pre-treatment proteinuria (n=6), masitinib treatment was discontinued due to lack of efficacy in three dogs, and three were euthanased during treatment, two for disease progression and one for an unknown reason.
Dr Margaux Kuijlaars, corresponding author for the paper, said: “Patients developing proteinuria should be investigated to exclude non-renal causes. This should allow for more informed recommendations on the monitoring and management of proteinuria and further masitinib treatment in these patients to be made. Masitinib treatment can be considered in patients with pre-treatment proteinuria and does not inevitably cause worsening of proteinuria.
“The findings of this study add to the evidence base for the use of masitinib in treating neoplasia in small animal patients. The use of masitinib in dogs in this study was off-licence as C-KIT MCT expression was not determined, and many dogs were treated for other tumours.”
Nicola Di Girolamo, Editor of JSAP, said: “Little is known about which dogs are predisposed to becoming proteinuric following treatment with masitinib for neoplasia. Due to the small number of dogs in this study that developed proteinuria, conclusions about predisposing factors cannot be definitely drawn.
"The findings of this study add to the evidence base and demonstrate the need for larger, prospective trials including a control population and longer period of follow-up.”
The full article can be found in the August issue of the Journal of Small Animal Practice and can be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13305. It is open access and can be freely accessed by anyone.
Reference
The £35 course is aimed at veterinary surgeons, veterinary nurses, receptionists and practice managers who may be faced with difficult and sensitive conversations around pet loss with clients. It covers:
Empathy vs sympathy
Communicating with active listening skills
Open questions
Face-to-face emotional support, telephone support, email support and other written communication
The Blue Cross says that the new course complements its £280, eight-week 'Pet Bereavement Support' course for more in-depth training, and also its hourly webinars, which cost £20.
The eight-week course requires a minimum of three to four hours of study per week and counts towards 32 hours Continual Professional Development.
For specific needs, the Blue Cross can also work with practices to provide bespoke face-to-face training across the UK, specifically tailored and delivered at the practice.
For more information, visit www.bluecross.org.uk/pbss-course or call 01993 867216.
Carprodyl Quadri is a pork-flavoured, four-way break tablet, available in two presentations of 50mg and 120mg. Each tablet offers four dosage strengths, designed to help you prescribe more accurately for a dog’s weight with fewer boxes on the shelves.
Part tablets can be kept in the blister pack for up to 72 hours, so clients can take home the exact amount of carprofen they require, thereby reducing cost and waste.
To support the launch of Carprodyl Quadri, Ceva is launching a range of marketing materials for veterinary practices. They include: dosage charts, dispensing envelopes, remember to order stickers to stick on boxes left on the shelves, reminder cards about the change for reception and dispensaries and client letters explaining why their prescription has changed.
Lucy Vernon, product manager at Ceva Animal Health said: "Carprodyl Quadri is an easy to administer carprofen that provides accurate dosing while reducing cost and waste and is a welcome addition to our popular pain management portfolio."
For further information, contact your local Ceva Animal Health territory manager.
All practices are eligible to register and no FCA authorisation is needed.
Carefree Credit says it will also process applications to make practice administration hassle free.
Mike Aldred, Director at Carefree Credit, said: "With the deepening cost of living crisis, owning a pet has never been more expensive for many pet owners and having these longer terms available will really help their pets get the treatment they need."
To register your practice with Carefree Credit, email office@carefreecredit.co.uk or call 0345 313 0177.
https://www.carefreecredit.co.uk
Vétoquinol has released the results of a survey of 1000 dog owners, which looked into their attitudes towards long-term medication for their pet1.
Owners were asked to rate how important various factors were to them when it came to giving medicine long term to their dog. They were also asked to consider what they felt was most important to their vet when it came to choosing a medicine.
Vétoquinol says the fact that dog owners rate the effectiveness of a medication much more highly than the cost means there is very little reason to compromise on treatment based on a presumption of what clients will want to pay. These findings are also largely very positive in that they suggest that dog owners believe that in many areas vets are making decisions based on criteria that are important to owners. The area where there is the greatest mismatch is over the risk of side effects of medication.
Pet owners think that vets may take the risk of side effects from long-term medications less seriously than the owners themselves might prefer. It suggests that the risk of potential harm, no matter how small the risk of actual harm is, may be more unacceptable to the dog owner than vets and nurses might otherwise presume. When prescribing long-term medication there is a need to talk about the risks associated with medication more openly and to take the client's attitudes to risk into consideration.
1. A survey of 1048 dog owners, carried out by petbuzz, on behalf of Vétoquinol, March 2011
Axiom Veterinary Laboratories has launched SLIT - sublingual immunotherapy treatment - for allergies in cats, dogs and horses.
According to the company, sublingual immunotherapy has been shown to be safe and effective in humans for over 20 years and a recent study has shown it to be a beneficial alternative way of administering immunotherapy to cats, dogs and horses, proving particularly effective in treating animals that failed to respond to allergy shots.
Patients can convert from shots to drops with an initial treatment kit.
Martyn Carpenter, Director of Axiom Laboratories Ltd, said: "Each ACTT Allergy Drop prescription is a custom formulation containing the specific allergens that are causing the pet's discomfort. Allergy drops are prepared in a glycerin solution to provide antigen stability, and have a slightly sweet taste, which assists in palatability and ease of administration. This method greatly reduces irritation and the likelihood of anaphylactic shock and can be administered easily at home by the client, freeing up consult slots and removing the stress which accompanies a visit to the surgery for many pets. This can be a particularly suitable alternative for those clients on a restricted budget, for whom on-going consult and injecting fees can be prohibitive to compliance with immunotherapy treatment. "
For more information, contact Axiom's Diagnostic Support Team on 01626 355655
Time spent discussing the articles can be claimed towards the annual CPD requirement by pressing the ‘Claim CPD’ link at the top of the forum discussion thread.
The first article up for discussion is “What diet should we feed a cat or dog with cancer?”, by Owen Davies, who will be joining us in the forum.
Owen is an RCVS, American and European Specialist in Veterinary Oncology working at Highcroft Referrals.
He graduated from Cambridge in 2005, worked in rural practice for three years, followed by a spell working for charities and then at a large hospital.
In 2014, he moved to the RVC to specialise in oncology before joining Highcroft in 2017.
VetSurgeon.org Clinical Editor, Alasdair Hotston Moore said: “For general practitioners, I think this adds a really valuable extra dimension to your clinical reading.
“It’s not just the opportunity to ask questions of the author, but also to discuss the implications and practicalities of the article amongst yourselves.
VetSurgeon.org Editor, Arlo Guthrie added: “More than that, it’s also in a closed professional community where you can be 100% confident of a friendly atmosphere and authoritative opinions with provenance.
“And more even than that, the questions you ask and the discussion you have are then available as a useful, searchable resource for everyone in the profession.”
So do come and join in.
First read the article here: https://www.veterinary-practice.com/article/what-diet-should-we-feed-a-cat-or-dog-with-cancer
Then come and join the discussion here: https://www.vetsurgeon.org/001/veterinary-clinical/small-animal/f/misc-case-discussions/30507/new-clinical-article-club-what-diet-should-we-feed-a-cat-or-dog-with-cancer-with-owen-davies
Hill's Pet Nutrition has announced that it will not be exhibiting at the British Small Animal Veterinary Association Congress this year, and instead will be found in a restaurant round the corner called The Strada.
The press release containing this news fluttered in at almost exactly same time as one from the BSAVA, in which President Grant Petrie revealed that Congress already has a record-breaking exhibition.
Hill's' spin on the story is that it's all part of a new way of thinking about how the company does business. Blake Hawley, DVM and Managing Director at Hill's Pet Nutrition said: "It's easy to fall into the same old habits and routines. In fact, it can be enormously comforting to predict that in the year ahead, one will deliver, and probably receive, expected results. We don't think that's really quite good enough. So, we made the difficult and very conscious decision to question what we do and challenge how we think about the way we do business."
Hill's goes on to say that it will continue to support BSAVA and help provide a great experience for people attending the Congress, by offering free Italian food, coffee or a glass of beer or wine from its new restaurant location.
Some might call that supportive of BSAVA. Others, less generous, might call it a way of benefitting from all the work that the BSAVA does to bring everyone together at Congress without contributing towards the costs.
Thankfully, though, it doesn't look like BSAVA has been hit that hard by the news. Grant Petrie said: "BSAVA is a not-for-profit registered charity, and Congress is run by vets and nurses. So all of us - organisers, delegates and exhibitors - are supporting the veterinary profession simply by being involved. Together, we are officially part of a record breaking year - with 241 exhibitors in the NIA, along with our fellow associations in the ICC.
"That's more than we've ever had before, and there is a waiting list of companies wanting to join us at this flagship event. So every company who is seriously committed to vets and being involved in supporting the small animal veterinary profession will be with us in the NIA. BSAVA really appreciates the involvement of exhibitors in making Congress such a vital event in the veterinary calendar. It means that not only can we offer remarkably cost-effective CPD, but also provide a showcase of new advances in the industry and the opportunity to get the most from your practice budget. It is where budget holders get the best value, and where exhibitors can meet key decision makers.
"Plus, of course, there's a lot of fun and plenty of free gifts to be found in the NIA too!"
As of today, veterinary surgeons in the UK can call themselves 'Doctor', following a decision made by the RCVS Council.
The decision to allow the use of the courtesy title followed a consultation which received 11,202 responses, of which 81% were in favour of the change, 13% against, and 6% did not mind either way.
The College says the idea is to align the UK with international practice, provide greater clarity for the profession and offer reassurance to clients and the animal-owning public that all veterinary surgeons registered with the RCVS, regardless of where they qualified, have veterinary degrees of an appropriate standard. Most international veterinary surgeons use the title and, in Australia and New Zealand, this is frequently tied to registration and professional standing, rather than necessarily academic attainment.
RCVS President Professor Stuart Reid said: "I am very pleased that the response from the consultation gave Council such clear direction and has allowed us to bring UK vets in line with the majority of veterinarians worldwide. It was my privilege to pose the question, which has been well and truly answered by the profession and the public.
"Whether one regards the decision as correcting a historical anomaly or simply providing greater clarity at home and abroad, there is no doubt that the issue has generated huge interest. Yet regardless of whether individual vets choose to use the title, it will not change the profession's ongoing commitment to the very highest of standards."
Nearly 50% of respondents to the consultation were veterinary surgeons, 22% veterinary students, 21% animal-owning members of the public, and the rest were veterinary nurses, veterinary nurse students, practice managers and non-animal-owning members of the public.
RCVS CEO, Nick Stace said: "I am delighted that such a strong message came from both the public and the profession on this issue. We have a responsibility to maintain confidence in the veterinary profession and this move will help underline to the public in particular that veterinary surgeons work to very high standards, regardless of where they qualified."
Use of the title is optional, and guidance has been produced to support the change. It stresses that veterinary surgeons using the title should be careful not to mislead the public, and that it is important that the use of 'Doctor' or 'Dr' by a veterinary surgeon does not suggest or imply that they hold a medical qualification or a PhD. If the title is used, the veterinary surgeon should use it in conjunction with their name and either the descriptor 'veterinary surgeon' or the postnominal letters 'MRCVS'.
The guidance is available as part of supporting guidance chapter 23 to the RCVS Code of Professional Conduct for Veterinary Surgeons, and can be read online at www.rcvs.org.uk/advertising (see paragraphs 23.6-23.8).
Veterinary surgeons may start using the title straight away; details about how their RCVS Register entry can be updated will be issued over the coming months.
The association has also compiled free access special collection on backyard poultry in the BSAVA library which is available until the end of December 2019.
The BSAVA's Q&As on avian influenza in backyard poultry are:
What is avian influenza?Avian influenza (AI) is highly contagious viral disease that affects both domestic and wild birds. AI viruses are usually classified into two categories: low pathogenicity avian influenza (LPAI), which typically causes no or very few clinical signs in poultry, and high pathogenicity avian influenza (HPAI) which typically causes high mortality rates in poultry1.
What are the clinical signs of disease in poultry?The type and severity of clinical signs displayed will be dependent upon the strain of the virus and the species affected; some species such as ducks and geese may show few clinical signs2.
How is the disease spread?Wild bird species are the natural host and reservoir for all types of avian influenza, naturally carrying the virus in their respiratory and intestinal tracts, commonly without developing signs of the disease1,3. The virus is predominantly spread via body secretions, both directly and indirectly2. Migratory birds (predominantly waterfowl and gulls) can spread the disease over a wide geographical area3.
Why is the winter a higher risk period for avian influenza? The UK is at increased risk of avian influenza from migrating birds during winter2. Furthermore, avian influenza viruses are able to survive for prolonged periods of time in the environment, particularly in low temperatures4.
How can I prevent my birds from contracting avian influenza?All keepers of poultry should ensure that they uphold good levels of biosecurity to prevent disease entering their flock. This includes:
maintaining good levels of hygiene and regularly disinfecting hard surfaces;
changing shoes before entering/leaving to avoid transferring faeces in/out of the poultry enclosure;
minimizing contact with wildlife by humanely controlling rodents and deterring wild birds. Contact with wild birds can be minimized by placing food and water in an enclosed area such as the coop, and preventing poultry from accessing ponds/standing water frequented by wild bird populations, for example by erecting temporary fencing;
where possible, keeping birds of different poultry species separate (e.g. ducks and geese should be separate from chickens).
Whilst it is important that all backyard keepers maintain good levels of biosecurity, it is particularly prudent for keepers in areas deemed at higher risk of an incursion of avian influenza. In Great Britain, a number of High Risk Areas (HRAs) have been identified based upon previous experience, scientific expertise and veterinary opinion, and are predominantly areas where large numbers of migratory wild birds gather. To find out whether you are in a HRA, use the interactive map.
What should I do if I suspect avian influenza?Avian influenza is a notifiable disease. If it is suspected, it must be reported immediately:
In England, contact the Defra Rural Services Helpline on 03000 200 301
In Wales, contact your local Animal and Plant Health Agency (APHA) office on 0300 303 8268
In Scotland, contact your local Field Services Office
For keepers in Northern Ireland, contact your local DVO.
References
Mr Wood faced three charges, all relating to allegations of misconduct over a laboratory test for an alpaca while he was working at a practice in South Oxfordshire.
The charges alleged that in September 2023, Mr Wood told the alpaca’s owner that it had tested positive for Johne’s disease when in fact, the animal had not been tested.
He then allegedly sent a letter confirming a positive test result for the test that had not taken place, and then created a false test result report in the name of a veterinary surgeon colleague and sent it to another colleague by email.
He later told the alpaca's owner that he had given her the wrong result by mistake and that the test result was actually negative.
Then in October 2023, he emailed the laboratory saying that a member of his practice’s administrative staff had written the false report.
In November he told the managing partner of his then employer on three occasions that he was investigating the false report in order to find out who sent it.
Finally, he sent a misleading and dishonest email to a veterinary surgeon colleague falsely indicating that a member of the practice’s staff had manufactured the false report, when that was not the case.
At the outset of the hearing Mr Wood admitted the facts of all the allegations against him.
Having found the facts proven, the Committee found that the charges amounted to serious professional misconduct, something which Mr Wood himself also admitted.
The Committee identified a number of aggravating factors in Mr Woods' conduct, including his lack of honesty, probity and integrity, the fact the conduct was premeditated, that it involved a breach of the client’s trust, the abuse of his professional position, the fact the conduct was sustained and repeated over a period of time, and that his conduct contravened advice given by the RCVS.
The mitigating factors included positive testimonials from professional former colleagues and client farmers, the fact that he had engaged in some remediation in order to avoid repeating the dishonest behaviour, and that he showed significant insight into his misconduct.
Dr Neil Slater MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee recognised that the serious repeated dishonesty, which was to conceal wrongdoing, made the respondent’s misconduct particularly serious.
“It therefore gave consideration as to whether his conduct was fundamentally incompatible with being a veterinary surgeon and whether removal was the only appropriate and proportionate sanction in this case.
“The Committee considered that this was a particularly difficult case to reconcile, as, on the one hand the misconduct was so serious whereas on the other hand, the respondent had demonstrated significant insight; the risk of repetition was low; the evidence of his professional achievements was strong and the testimonials from client farmers and professional colleagues were impressive.”
He added: “The Committee considers that suspension is sufficient in the circumstances of this case to satisfy public confidence in the profession and to uphold proper professional standards of conduct and behaviour.
"The Committee therefore imposes a suspension of 18 months on the respondent.
"In determining this length, the Committee considered that this was the least period necessary in order to meet the significant public interest considerations in this case.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Chanelle has announced the launch of Ketamidor 100 mg/ml Solution for Injection (ketamine), licensed for use in cats, dogs, horses, cattle and swine in the UK and Ireland.
The company says the new product provides a versatile addition to anaesthetic regimes. It can be used in combination with other widely-used anaesthetics and sedatives. Chanelle says it also has analgesic properties that make it particularly beneficial to include in anaesthetic protocols when carrying out painful surgical procedures.
Ketamidor 100mg/ml Solution for Injection has a zero day withdrawal period for milk and meat when used in cattle and pigs, allowing high welfare standards to be maintained without compromising economic returns.
According to Chanelle, ketamine is now experiencing a resurgence of interest as its analgesic properties and minimal impact on spontaneous respiration become increasingly appreciated.1
Angela Wilkin, Chanelle UK's Sales and Marketing Manager said: "Ketamidor makes a great addition to our portfolio of pain management products. Our territory managers are looking forward to speaking to those vets who are already accustomed to using ketamine and those that may be considering adding it to their current protocols."
When you post a job advert, or a shout for assistance on VetSurgeon Jobs, it is emailed to subscribers immediately and fed out onto other social networks. You can further extend the reach of your post by sharing it yourself and (with "Share and reward") encouraging other members of your team to do likewise.
I have taken the decision to drop the charge for advertising because it seems very clear now that we all face a very grim few months ahead, and it has never been more important that we all pull together and support each other, both personally and in business.
Of course, removing the charge for advertising for help on VetSurgeon.org and VetNurse.co.uk is not, in and of itself, going to save anyone from going under, but I hope perhaps other veterinary suppliers might follow my lead and consider dropping their prices until such time as everyone is back on their feet.
I have a number of other ideas in the pipeline, all designed to help bring the profession together and support each other, which I will announce shortly.
In the meantime, there's a forum discussion for sharing ideas to make the next few months more bearable, here: Getting through coronavirus. Do come and share your thoughts, and I will email the best ideas to all members.
And take care, everyone.
Clinicians at the Queen Mother Hospital for Animals at the Royal Veterinary College have become the first team in the UK to successfully treat acromegaly in a cat with hypophysectomy surgery.
According to the RVC, this make it the first centre in the UK, and only the fourth in the world, to offer this procedure. The patient groups that might benefit from this RVC-exclusive procedure include cats and dogs with non-functional pituitary tumors, cats and dogs with hyperadrenocorticism (Cushing's disease) and cats with acromegaly or hypersomatotropism.
The RVC says removing the pituitary gland and the associated tumour which causes acromegaly or hyperadrenocorticism is the gold standard treatment in humans suffering from these diseases since it offers the greatest chance of a complete cure for the disease.
Prior to the RVC offering surgical treatment, the only treatment options available for acromegalic cats in the UK were radiation therapy or simply treatment of the resulting diabetes mellitus. The latter can prove extremely difficult and frustrating and the former unpredictable, unreliable and/or ineffective. Even when a complete response to the radiation therapy eventually occurs, hormonal abnormalities usually persist.
Dr Stijn Niessen, leading the hypophysectomy team at the Royal Veterinary College, said: "I'm extremely proud to be able to offer this unique surgery for the first time in the UK at the RVC. As a relatively new and innovative procedure in veterinary medicine there are risks involved, as is recognised with every form of neurosurgery of this level. However, despite these risks, this surgery does offer owners a chance for the best possible result for their pet using a single procedure. Hypophysectomy therefore represents the most elegant treatment method currently available enabling complete removal of the brain tumor and normalisation of damaging excessive hormone levels that are causing hormonal diseases like acromegaly and hyperadrenocorticism.
"Especially when a pituitary tumor is diagnosed late, the alternative treatment method of radiation therapy might well take too long to take effect and devastating neurological signs might occur due to the pressure of the pituitary tumor on the surrounding brain. In such cases, hypophysectomy can make an instant difference in relieving that pressure. However, in general, we would advocate the procedure to be considered as soon as possible following diagnosis, thereby preventing the animal's body from becoming more and more negatively affected by the excessive hormone levels associated with pituitary diseases like acromegaly and hyperadrenocorticism."
Dr. Niessen, a European Veterinary Specialist in Internal Medicine with research interests in diabetes and endocrinology and world-expert in acromegaly, will be selecting the patients suitable for the new treatment, preparing them for surgery and managing the aftercare programme. The longer-term aftercare programme will include hormone replacement treatment administered through eye-drops (usually temporarily) and tablets (permanent) to manage the hormone production lost through removal of the pituitary gland.
The surgery itself will be performed by Patrick Kenny, a European and American Specialist in Veterinary Neurology and Neurosurgery.
The RVC says the surgery would not be possible without the multidisciplinary approach at the Queen Mother Hospital for Animals, which includes the Internal Medicine, Neurology and Neurosurgery, Diagnostic Imaging, Anaesthesia and Emergency and Critical Care teams as well as a team of highly qualified nurses.
To support ongoing research in this field, the Royal Veterinary College is offering free blood tests for all diabetic dogs and cats which include fructosamine evaluation and screening tests for the presence of acromegaly in cats. Cats that record high hormone levels indicative of acromegaly will qualify to undergo a free CT scan for confirmation. If acromegaly is confirmed, all possible treatment options will be discussed with the client, including the hypophysectomy procedure. To request a free blood test for a patient please visit: www.rvc.ac.uk/cic
Veterinary surgeons currently managing a cat or dog with a pituitary tumor who are considering referral of this case can also contact Dr Stijn Niessen for further information at the QMHA on 01707 666365 or at qmhreception@rvc.ac.uk
The charges related to the unexpected death of a cat called Hope during an operation to explore a growth in her mouth, and Dr Dantas-Holmes' subsequent communication with the animal's owners.
Dr Dantas-Holmes accepted that Hope’s death was most likely due to her failing to flush fluid through the giving set attached to an intravenous drip, leaving air in the tubing and causing some air to enter Hope’s bloodstream when the cannula was placed and the giving set’s control opened.
The first set of charges related to Dr Dantas-Holmes’ initial phone call to Hope’s owners ten minutes after Hope’s death, in which she said that Hope had died because of a reaction to anaesthetic drugs. Dr Dantas-Holmes failed to mention that the cause of death was still to be determined and failed to mention that a likely cause was in fact an air embolism and/or a complication relating to the intravenous drip.
Following her initial phone call to the owners Dr Dantas-Holmes viewed CCTV of her actions.
The owners then came into the practice later in the day, and the communications during that time constitute the second set of charges: that, during this meeting, Dr Dantas-Holmes didn’t correct her earlier statements about the cause of Hope’s death, and that she didn’t mention that there was an ongoing investigation or that a likely cause of death was an air embolism and/or complication.
The third set of charges related to Dr Dantas-Holmes’ subsequent clinical records, in which it was alleged that she failed to include references to the findings on review of the CCTV footage of Hope’s death, and the possibility of an air embolism and/or complication relating to the intravenous drip.
The fourth and final set of charges were that her conduct was misleading, and/or dishonest.
With regard to the first set of charges, the Committee found that Dr Dantas-Holmes did tell the owners that Hope died because of a reaction to the drugs, but that given the short nature of the phone call to the owners and the distressing circumstances there was no duty to discuss the investigation, or to mention the likely cause being an air embolism.
Concerning the communications with the owners when they came to the practice, the Committee found that Dr Dantas-Holmes did fail to mention that anaesthetic drugs might not have been the cause, and that she also failed to mention the investigation. Dr Dantas-Holmes had agreed with the Practice Manager, however, that she would not discuss the possibility of an air embolism or complication, and so that charge was not found proved.
On consideration of whether Dr Dantas-Holmes had failed to include relevant findings in the clinical reports, the Committee found both charges proved, and, in relation to the final set of charges, the Committee found that while Dr Dantas-Holmes had misled Hope’s owners, it was unintentional, and she had not been dishonest.
Ultimately, the Committee found Dr Dantas Holmes not guilty of disgraceful conduct in a professional respect.
Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The findings of this Committee demonstrate that there were errors and omissions in communications with the owners. When communicating with a client it is the professional’s responsibility to ensure that the client has heard and understood what has been said. The importance of good and effective communication is particularly important when an unforeseen and shocking event occurs such as it did in this case.
"The particular circumstances of this case demonstrate how important it is to communicate effectively and the need for the veterinary surgeon to ensure that their clinical records for which they are wholly responsible, are complete.
"The Committee concluded that its findings demonstrated a departure from professional standards but that the falling short was not so grave as to amount to disgraceful conduct in a professional respect."
For the study1, the authors Lucy Norris, Gina Pinchbeck, Peter-John Noble and Alan Radford, analysed data from electronic health records submitted by veterinary practices participating in the Small Animal Veterinary Surveillance Network (SAVSNET).
They found that a total of 132 dogs with cropped ears were seen by vets across a sample size of 500 practices between 2015 and 2022, with numbers peaking in 2021.
The breeds most likely to have cropped ears were the American bulldog, Dobermann, Italian mastiff and bulldog.
In more than 60% of the cases, the dogs had been imported from countries where ear cropping is illegal, such as Romania, Hungary, Bulgaria, Serbia, Spain, Poland and Ireland.
The authors acknowledge that the findings of their research are likely just a small snapshot of the true scale of the ear cropping problem: figures from the 2022 PDSA PAW Report suggest that the true numbers of dogs imported with cropped ears could be as high as 26,000.
RSPCA Head of Companion Animals Samantha Gaines said: "The study provides strong evidence to refute arguments for ear cropping to prevent ear infections, as the breed types identified in Norris and colleagues’ study are not generally predisposed to such infections.
"Rather, this finding adds weight to anecdotal evidence suggesting that the motivation for ear cropping in many dogs is driven by appearance rather than any perceived health benefits.
“It is also possible that some dogs were cropped illegally in the UK using legal importation as a smokescreen for this activity.
"Indeed, it is the RSPCA's experience that many dogs stated as being cropped outside of the UK have histories that would make this highly unlikely.”
Vet Record editor-in-chief Suzanne Jarvis said: “One solution to the importation problem is proposed in the Kept Animals Bill, which is currently stalled in parliament.
"Although there could be potential for fraud around grandfather rights initially, a ban on such importations would ultimately mean that the sight of a dog with cropped ears becomes a thing of the past in the UK.”
https://www.bva.co.uk/take-action/ear-cropping-campaign
Vetoquinol is launching Cimalgex, a new NSAID for dogs this month.
Cimalgex (cimicoxib) is a new second generation COX-2 inhibitor which can be used for the treatment of pain and inflammation due to osteoarthritis and the management of peri-operative pain associated with orthopaedic and soft tissue surgery, for which it can be given two hours before surgery and continued for 3-7 days post surgery.
Vetoquinol says that an important consideration in treating dogs with osteoarthritis, many of which are geriatric, is that there are no contraindications to using Cimalgex in patients with mild to moderate renal impairment.
According to the company, field trials showed that over 90 per cent of per owners and vets identified that animals experienced excellent analgesia post operatively*.
Available in a chewable, splitable tablet, Cimalgex can be given with or without food.
Vetoquinol says that the excellent tolerability, efficacy profile and ease of use of Cimalgex means that veterinary patients could benefit from pain relief in situations where clinicians are worried about the risks versus the benefits of prescribing a NSAID for pain management.
Further information about assessing pain and decision making when it comes to prescribing NSAIDs, will be presented in a free webinar on 19th October at 8.30pm. To register go to www.thewebinarvet.com/vetoquinol and enter code CIM1.
Reference*E. Grandemange: Field evaluation of the efficacy and the safety of cimicoxib in the relief of peri-operative pain in dogs; 2008, study number n°3008C2F1
The urinary products, which are made to provide tailored nutritional solutions for cats and dogs with urinary issues, are available in both wet pouches and dry kibble.
The company simultaneously introduced a new urinary diagnostic tool: the Royal Canin Hematura Detection by Blücare.
The tool is made up of granules which are put in a cat’s litter tray and which turn blue if they detect blood in the urine. Royal Canin says it is a revolutionary diagnostic aid that will be able to prevent feline lower urinary tract disease developing any further.
John O’Connor, Corporate Affairs Director at Royal Canin, said: "We are constantly looking to evolve our offer and provide the very best in nutrition. We have simplified our ranges making it easier to navigate and choose the right product for each cat and dog, created a new premium pack design and developed our best veterinary nutritional solutions.
"It was imperative that we worked very closely with the veterinary community in making this bold transformation so we consulted with vets and vet nurses, in addition to pet owners from across the world."
Mr Smith was convicted of conspiracy to commit a fraud in which potentially dangerous horses were drugged and then sold to unsuspecting owners, at Maidstone Crown Court in June 2016. He was given 30 months' imprisonment, which formed one of the charges heard by the Disciplinary Committee.
There were also a number of charges related to his treatment of five different animals while in practice at the Lakeview Veterinary Centre in Folkestone, Kent. The charges were:
In relation to a Clydesdale mare named Grace on 14 August 2014 he failed to perform an adequate examination and/or undertake sufficient investigation and/or take a history of her; that after his initial visit to Grace on that day he failed to respond adequately to the owner’s telephone reports that Grace had deteriorated and/or failed to improve; and, that he failed to make adequate clinical records for Grace.
Between 29 September 2014 and 31 January 2015, in relation to a Labradoodle named Holly, he failed to keep adequate clinical records.
In relation to a cat named Maisey the allegations were that he failed to examine and investigate the cat adequately, he made a diagnosis of diabetes mellitus and gave insulin to administer to the cat without first undertaking the minimum investigation required, failed to keep adequate clinical records and sent an incorrect, misleading and dishonest statement to the RCVS regarding his treatment of Maisey. All charges date between 30 October and 19 December 2014.
In relation to a cat called Comet the allegation was that between 1 April and 17 April 2015 he failed to keep adequate clinical records and failed to respond adequately and appropriately to concerns raised by the owner.
Regarding a Yorkshire Terrier with diabetes named Poppy the allegation was that in two emergency out-of-hours calls made by Poppy’s owner to Mr Smith in April 2015 regarding the dog’s condition, he failed to recommend veterinary treatment or keep adequate clinical records. Furthermore, when the owner attended the practice following the two calls and the death of Poppy, he attributed the care to another member of the practice and failed to communicate effectively with the owner.
Having heard from a number of witnesses, including Mr Smith, and having received representations from Mr Smith in relation to the above charges, the Committee found almost all of the charges proven, with the exception of those relating to Mr Smith’s alleged conversation with Poppy’s owner at the practice following her death.
The Committee then went on to consider whether the various proven charges amounted to disgraceful conduct in a professional respect and whether the conviction rendered Mr Smith unfit to practise veterinary surgery.
In relation to the clinical charges the Committee found that, both individually and cumulatively, they amounted to disgraceful conduct in a professional respect.
The Committee also determined that the conviction rendered Mr Smith unfit to practise veterinary surgery and noted that it involved prolonged dishonesty, breach of trust, disregard for animal health and welfare and a "total abrogation of Mr Smith’s professional responsibilities."
Cerys Jones, chairing the Committee and speaking on its behalf, said: "The Committee was particularly concerned because the dishonesty went to the heart of Mr Smith’s responsibilities as a veterinary surgeon. His registration as a veterinary surgeon enabled him to take part in the conspiracy, and that role involved him conducting certified examinations on animals and supplying drugs for administration to animals. Reliable and honest certification is a vital element of the veterinary surgeon’s public role."
In considering the sanction against Mr Smith the Committee looked at the clinical charges and the conviction separately.
In relation to the clinical charges the Committee found that his treatment of the animals in these cases was fundamentally incompatible with being a veterinary surgeon. The Committee therefore directed that Mr Smith’s name should be removed from the Register of Veterinary Surgeons.
The Committee said that the case demonstrated that Mr Smith’s lack of treatment or his inappropriate treatment of these animals caused harm and that in some regards, for example the writing of accurate and contemporaneous clinical notes, Mr Smith demonstrated a total disrespect for the Code of Professional Conduct.
The Committee went on to say: "Further, he deliberately lied to his regulator. He demonstrated deep-seated attitudinal issues including a misplaced belief in his own abilities and had no insight or commitment to do anything different in the future. In those circumstances the likelihood of repetition was significant in the Committee’s view."
In considering the sanction for his conviction of conspiracy to commit fraud the Committee took into account a number of aggravating factors including the premeditated nature of the conduct, the fact it was repeated over four years and the fact that harm was caused to both animals and people as a result of his actions.
Cerys Jones said: "As the decision notes, some of the riders were novices or children and as a result of their experience they lost confidence in riding a horse. As the independent veterinary surgeon Mr Smith was in a position of responsibility because he was certifying the horses as to their suitability. A particularly aggravating feature in this case is that Mr Smith had previously been removed from the Register for falsely certifying horses for export."
In relation to the conviction the Committee also directed that the Registrar remove Mr Smith from the Register.
Mr Smith has 28 days from being informed of the Committee’s decision to make an appeal against it.
The full findings can be found here.
VetUK, an online supplier of pet products and veterinary prescription only medications, has announced that it now processes over £750,000 worth of online transactions per month.
The point of the press release was to highlight that this has been achieved using paypoint.net to handle the tens of thousands of orders that VetUK says it receives each month, and process the payments.
However, it does also highlight the ever growing competition to veterinary practices from online. You might like to check VetUK's POM prices here.